Clinical Trial

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-01-22; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06788938
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Amgen
Conditions DLL3-expressing Tumors, Advanced Tumors
Enrollment 29 participants
Start Date 2025-03-21
Primary Completion 2028-04-24 (estimated)
Study Completion 2029-04-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-18